From trials: dose-dependent GI effects (nausea, vomiting, diarrhea); the glucagon arm raises questions about heart rate and other metabolic effects still being characterized.

• Incompletely known: because there's no Phase 3 or long-term data, the full safety profile is genuinely not established — this is not reassurance, it's a data gap.

• Off-label/gray-market-specific: self-dosing an investigational triple agonist with no approved dosing guidance, from unverified vials, is dosing in the dark.

Sourcing red flags - Retatrutide is the poster child for the sourcing risk:

• Mislabeling is documented and directly relevant: independent testing has found vials labeled retatrutide that actually contained semaglutide — a different drug at a different potency. You cannot assume a "reta" vial is retatrutide.

• "99% purity" ≠ identity or dose: purity claims don't confirm the vial is even the right compound.

• Censorship-evasion slang compounds the risk: buying something called "GLP-3" or "ratatouille" means many users don't even know the formal identity of what they're injecting.

• No approved manufacturer exists, so there is no regulated supply to fall back on.

• The flat-feeling signal (emerging — low evidence tier). A growing number of people report emotional blunting on GLP-1 drugs — reduced libido, feeling numb, loss of interest in relationships. The mechanism is plausible: GLP-1 receptor activity dampens dopamine signalling in the brain's reward circuitry, which is why it quiets "food noise" and alcohol craving — but that dampening doesn't necessarily stop at food. The evidence is patient reports, case reports, and mechanism — not randomized trials; no RCT has measured it with a validated instrument. The honest nuance: the same reward-dampening that helps someone with a dysregulated reward system can flatten someone whose reward system was healthy, and you often can't tell from the inside which is happening. If the people around you notice you've gone flat, take that as seriously as any physical side effect. → See the full discussion on Reward, motivation, and the flat feeling.

• Grey-market retatrutide is already generating real-world harm reports. Retatrutide is not approved anywhere — it exists only as trial data and grey-market vials. In 2026 the BMJ ran a fact-check examining a reported death in a man using the unapproved weight-loss jab. Whatever the final verdict on any single case, the point stands: people are injecting an unapproved triple agonist bought online, at self-chosen doses, with no medical oversight — and the harm signal has reached the pages of a major medical journal. This is the exact gap between the trial data (promising) and the grey-market reality (unmonitored) that this site exists to name.